Clinical trial
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00234741 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00234741 |
|---|---|
| Title | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease |
| Official title | A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH National Institutes of Health (NIH) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | STA-5326 mesylate |
| Enrollment | 12 |
| Start date | Nov 1, 2005 |
| First posted | Oct 7, 2005 |
| Last update posted | Dec 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: